|STADA Arzneimittel Aktiengesellschaft -- USA Stock|| |
USD 104.04 0.000001 0.00%
Member of the Supervisory Board
Mr. Constantin Meyer was Member of the Supervisory Board of STADA Arzneimittel AG from 2003 to August 26 2016. Since 1974 He was Chairman of the Examination Board for Pharmaceutical Technicians and Assistants of the Lower Saxon Chamber of Pharmacists. He has previously worked as a control manager and pharmaceutical advisor. From 1986 to 1992 he was responsible for the growth of MEDICA MEYER until its merger with Phabil Bielefeld. In 1986 he became Chairman of the Advisory Board of STADA Arzneimittel AG. He studied pharmacy at LudwigsUniversitaet zu Freiburg in Breisgau Germany and gained his pharmaceutical licence in 1971.
Age: 72 Executive Since 2003
49 6101 603 0 http://www.stada.de
The company has return on total asset (ROA)
of 5.26 %
which means that it generated profit of $5.26 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 9.8 %
meaning that it generated $9.8 on every $100 dollars invested by stockholders.
The company has accumulated 1.79 B in total debt with debt to equity ratio (D/E) of 134.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 0.67 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel is traded on OTC Market in USA.STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Stadastrasse 2-18 and employs 11,117 people.